YPSN Share Price Performance
CHF 0
-371.50 (-100.00%)
Price CHF 0
Fair ValueCHF 359.75
Share Pricen/a
When Should You Buy Ypsomed Holding AG (VTX:YPSN)?
Nov 17
Ypsomed Holding AG Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 6 Fair Values set on narratives written by author
YPSN Community Narratives
AN
Fair Value CHF 359.75 11.6% undervalued intrinsic discount
Overcapacity And Regulatory Challenges Will Limit Future Potential
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value CHF 407.78 22.0% undervalued intrinsic discount
Analysts Revise Ypsomed Target Downward Amid Mixed Views on Growth and Margins
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value CHF 525 39.4% undervalued intrinsic discount
Connected Self-Injection Devices Will Redefine Chronic Care Globally
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Analysts Revise Ypsomed Target Downward Amid Mixed Views on Growth and Margins
Key Takeaways Ypsomed's shift to a B2B model and local manufacturing may streamline operations, improve focus, and reduce geopolitical risks, enhancing margins and earnings. Expansion in manufacturing capacity and a robust project pipeline positions Ypsomed for long-term revenue growth in self-injection and drug delivery systems.Read more
84
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
CHF 407.78
22.0% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
2.96% p.a.
Profit Margin
24.87%
Future PE
28.33x
Price in 2028
CHF 443.79
Overcapacity And Regulatory Challenges Will Limit Future Potential
Key Takeaways Heavy capital spending and reliance on sustained high growth risk overcapacity, margin compression, and stranded assets if demand falters. Dependence on major partners, regulatory risks, and heightened competition threaten revenue stability, pricing power, and long-term relevance.Read more
10
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
CHF 359.75
11.6% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
4.07% p.a.
Profit Margin
26.96%
Future PE
23.44x
Price in 2028
CHF 391.24
Connected Self-Injection Devices Will Redefine Chronic Care Globally
Key Takeaways Sharpened focus on high-margin self-injection systems and digital health devices is expected to sustainably improve margins and accelerate growth. Unique product portfolio and strong pharma partnerships position Ypsomed to benefit from industry outsourcing trends and surging demand for home-based care solutions.Read more
4
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
CHF 525
39.4% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
12.14% p.a.
Profit Margin
28.67%
Future PE
25.71x
Price in 2028
CHF 570.96
Trending Discussion
Recently Updated Narratives
AN
YPSN: Long Term Injectable Demand Will Support Future Earnings Resilience
Fair Value: CHF 407.78 22.0% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Overcapacity And Regulatory Challenges Will Limit Future Potential
Fair Value: CHF 359.75 11.6% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Connected Self-Injection Devices Will Redefine Chronic Care Globally
Fair Value: CHF 525 39.4% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Ypsomed Holding AG Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
May 20, 2026
- 14.22
- 39.29%
- 24.63%
- 1.2%
About YPSN
- Founded
- 1984
- Employees
- 2000
- CEO
- WebsiteView website
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication companies. The company operates through three segments: Ypsomed Delivery Systems, Ypsomed Diabetes Care, and Others. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
